Background Atrial fibrillation is the main cause of stroke, but the risk can be reduced, usually
with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study …

Objectives: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …

Objectives The introduction of new oral anticoagulants for the prevention of stroke in atrial
fibrillation (AF) has changed the clinical management of AF. To inform decision making …

Objective: To assess the cost-effectiveness of dabigatran etexilate ('dabigatran') vs vitamin K
antagonists (VKAs) in the Belgian healthcare setting for the prevention of stroke and …

Aims Patients with atrial fibrillation have a significantly increased risk of thromboembolic
events such as ischaemic stroke, and patients are therefore recommended to be treated with …

Background and Purpose—The cost-effectiveness of dabigatran for stroke prevention in
patients with atrial fibrillation and prior stroke or transient ischemic attack has not been …

Abstract Introduction and Objectives To estimate the cost-effectiveness and cost-utility of
dabigatran in the prevention of stroke and systemic embolism in patients with non-valvular …

Oral dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in
patients with atrial fibrillation (AF) in whom anticoagulation is appropriate. Based on the RE …

Canadian patients with atrial fibrillation (AF) in whom anticoagulation is appropriate have
two new choices for anticoagulation for prevention of stroke and systemic embolism …

Objective To assess the cost-effectiveness of dabigatran etexilate, a new oral anticoagulant,
versus warfarin and other alternatives for the prevention of stroke and systemic embolism in …